左卡尼汀治疗缺血性心肌病心力衰竭的效果

Effect of Levocarnitine on Heart Failure in Ischemic Cardiomyopathy

目的:研讨左卡尼汀对缺血性心肌病心力衰竭的治疗效果。方法:以2015年10月~2017年10月期间在某院接受救治的80例缺血性心肌病心力衰竭患者为研究对象,根据患者所用治疗方案为依据进行分组,将入组患者分成对照组和观察组。对照组实施常规疗法,给予观察组左卡尼汀治疗方式,对两组治疗效果进行比较。结果:对照组患者治疗总有效率为77.5%,观察组患者治疗总有效率为95.0%,差异存在统计学意义(P<0.05);对照组和观察组治疗前脑钠肽(BNP)和左室射血分数(LVEF)差异不具有统计学意义(P>0.05);两组患者治疗后BNP和LVEF对比,差异存在统计学意义(P<0.05)。结论:给予缺血性心肌病心力衰竭患者左卡尼汀治疗方案,可使治疗效果得到明显提升,有利于改善BNP和LVEF水平,值得在深入研讨的基础上进一步推广应用。

Objective: To study the therapeutic effect of levonetine on heart failure in ischemic cardiomyopathy. Methods: 80 patients with heart failure of ischemic cardiomyopathy who received treatment in a hospital from October 2015 to October 2017 were selected and divided into control group and observation group according to the treatment plan used by the patients. The control group received conventional treatment, the observation group was given the treatment of levocarnitine, and the therapeutic effects of the two groups were compared. Results: The total effective rate was 77.5% in the control group and 95.0% in the observation group, with statistically significant difference ( P <0.05).There was no significant difference in brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF) between the control group and the observation group ( P >0.05). There was significant difference in BNP and LVEF, between the two groups after treatment ( P <0.05). Conclusion: The treatment of levocarnitine in patients with heart failure of ischemic cardiomyopathy can significantly improve the therapeutic effect and improve the levels of BNP and LVEF, which is worthy of further promotion and application on the basis of in-depth study.